Last reviewed · How we verify
Vorapaxar and Clopidogrel
Vorapaxar and clopidogrel work together as dual antiplatelet agents to prevent blood clots by blocking platelet activation and aggregation through different pathways.
Vorapaxar and clopidogrel work together as dual antiplatelet agents to prevent blood clots by blocking platelet activation and aggregation through different pathways. Used for Acute coronary syndrome, Secondary prevention of atherothrombotic events in patients with stable coronary artery disease.
At a glance
| Generic name | Vorapaxar and Clopidogrel |
|---|---|
| Also known as | Group 2 |
| Sponsor | Inova Health Care Services |
| Drug class | Dual antiplatelet agent |
| Target | PAR-1 (vorapaxar) and P2Y12 receptor (clopidogrel) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Vorapaxar is a protease-activated receptor-1 (PAR-1) antagonist that blocks thrombin-induced platelet activation, while clopidogrel is a P2Y12 receptor antagonist that inhibits ADP-mediated platelet aggregation. Together, they provide complementary antiplatelet effects to reduce thrombotic cardiovascular events.
Approved indications
- Acute coronary syndrome
- Secondary prevention of atherothrombotic events in patients with stable coronary artery disease
Common side effects
- Bleeding
- Dyspnea
- Bradycardia
- Hypotension
Key clinical trials
- Vorapaxar on Thrombin Generation and Coagulability (PHASE4)
- Vorapaxar as an Add-On Antiplatelet Therapy in Patients With and Without Diabetes Mellitus (PHASE4)
- Trial to Assess the Safety and Effects of Vorapaxar in Japanese Subjects With Acute Coronary Syndrome (P04772; MK-5348-016) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vorapaxar and Clopidogrel CI brief — competitive landscape report
- Vorapaxar and Clopidogrel updates RSS · CI watch RSS
- Inova Health Care Services portfolio CI